about
Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccinationA DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primatesTargeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells.17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Identification of novel targets for the diagnosis and treatment of liver fibrosis.Emerging therapeutic targets for the treatment of hepatic fibrosis.Vitamin D3 inhibits TNFα-induced latent HIV reactivation in J-LAT cells.The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.Identification of novel chemotherapeutic strategies for metastatic uveal melanoma.The immunobiology of apotransferrin in type 1 diabetes.Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells.Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.Induction of OAS gene family in HIV monocyte infected patients with high and low viral load.Cyclin D1 and Ewing's sarcoma/PNET: A microarray analysis.CD4+ T-cell gene expression of healthy donors, HIV-1 and elite controllers: Immunological chaos.Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats.BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer.Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis.Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1.Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents.Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis.Acceleration of SLE-like syndrome development in NZBxNZW F1 mice by beta-glucan.Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat.Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9].Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis.Standardized bovine colostrum derivative impedes development of type 1 diabetes in rodents.Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.Expression of DNA methylation genes in secondary progressive multiple sclerosis.mTOR as a multifunctional therapeutic target in HIV infection.VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosusCo-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cellsHypomethylating Agent 5-Aza-2′-deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse ModelsNo-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ĆELIJA NESITNOĆELIJSKOG KARCINOMA PLUĆA RAZLIČITE OSETUIInfluence of lactoferrin in preventing preterm delivery: A pilot study
P50
Q28236770-F0A6BBAA-1C6A-4DDF-8FC5-43D1248EEF7FQ30398956-CDDCB997-A430-41B3-92BE-3875F0C074ECQ34173253-F3B2B6FE-B162-4E75-8024-1C1E21B0805AQ35399263-7515F4B3-18D3-4004-B500-A1112BD87187Q36294272-D7CCF181-9911-4A8F-8FA5-2187A9DFD9E0Q37865381-73DD1A48-6CA8-49D4-9C28-D2DA45CCAD47Q38461199-BCA93ED7-D26F-41C4-9FE6-2AB8EDBDB2EFQ38622303-532D25E7-2308-404B-8A68-83106544F88AQ38764819-9953A3EC-20DE-4A4E-98DE-6884475D262BQ38848393-660841CA-46D2-47C4-81DA-D2DFFC983087Q38901800-686291F0-2557-4344-A1D8-90C1C574D6F3Q39302816-C48E9D4D-F1AC-4934-A5D9-78291BF1F752Q39313996-5AF5A8BF-9617-415E-89E7-EC12291F1630Q39319803-26F18C9C-A2CC-4ED2-B236-7FE208D7A665Q39337196-D2D640DF-2C1F-4FAE-86FB-B3798C3D7D6CQ39389293-07EBE8B7-F531-4ADD-B06E-FEB9A1A2CD96Q39602151-0CFFB41E-8AF0-45D3-8B4E-E8F472C17672Q39827640-93924032-6BB3-4C2B-A52D-DBBEEEDCF67CQ40545742-F7F0795E-2F6A-48B9-8AA0-65EDF48D3771Q40701666-5B6C5149-31CC-4BF3-B776-0B4C272CF861Q41026728-83973A43-F26D-45E8-A9D9-754DBDB30DE5Q41472027-D796C878-E411-4D59-823C-3427FBE3BD13Q42417533-4E39796E-C33B-4866-86D8-DD0148F1BCB2Q43411949-E46DCD63-D890-466A-8301-7C634CFEABD4Q43629359-3B55195C-3841-4072-90AF-0E4CE9A3A632Q43709498-B5C2472C-3A88-481E-8DE3-E7CADE48E4EFQ45098771-B70B0407-B08C-49C9-B598-0E4BB9E00B01Q45362554-444D10B8-53EA-4F62-8516-28FA0FEE69A8Q46605939-04EA18DA-1EDA-4E52-B796-81DCAB65D9ACQ46896659-478B545D-07D3-4276-933F-52FA22316690Q47925346-4F0AEEFA-23DF-47A3-ABA3-BB06A18C8169Q51443240-EEA2EA89-D072-402B-9B25-4F3EF553E55CQ53297192-EA776434-A417-48D9-BCD8-0954FBD1A7DBQ53778920-6B20F1E5-AF4E-41C2-A63F-B788CB393183Q54586477-2FD4B67D-B64A-4CDA-A5D2-5DA9BDB60E9DQ57081512-95443844-BA53-4F17-AE08-72105659B619Q57081527-BE68160E-2DD1-45EB-B7F8-649E04C77BBAQ60981582-D48847C3-2733-4792-BB47-400FCE700D18Q60981597-BCAC2265-71C9-40A0-928E-A57DA18555F3Q60981602-19A6BBDC-FC73-49F4-8EAC-22FCB0145044
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Fagone
@ast
Paolo Fagone
@en
Paolo Fagone
@es
Paolo Fagone
@nl
Paolo Fagone
@sl
type
label
Paolo Fagone
@ast
Paolo Fagone
@en
Paolo Fagone
@es
Paolo Fagone
@nl
Paolo Fagone
@sl
prefLabel
Paolo Fagone
@ast
Paolo Fagone
@en
Paolo Fagone
@es
Paolo Fagone
@nl
Paolo Fagone
@sl
P1053
Q-4455-2016
P106
P1153
8748540600
P21
P31
P3829
P496
0000-0002-6694-1992